Navigation Links
Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
Date:12/27/2008

NEW BRUNSWICK, N.J., Dec. 27 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced that stockholders of Omrix Biopharmaceuticals, Inc. (Nasdaq: OMRI) ("Omrix") tendered approximately 16,749,152 shares of Omrix common stock, including approximately 1,293,924 shares subject to guaranteed delivery procedures, representing approximately 97.8% of Omrix's outstanding common stock. According to the terms of Johnson & Johnson's tender offer, shares that were validly tendered and not withdrawn have been accepted for payment. The tender offer expired at 12:00 midnight (Eastern time) on Dec. 26, 2008, and was not extended.

Johnson & Johnson intends to complete the acquisition of Omrix through what is known as a "short-form merger," that is, without a vote or meeting of Omrix's remaining stockholders. Each of the remaining shares of Omrix common stock (other than shares owned by stockholders of Omrix who properly exercised their appraisal rights under Delaware law) will be converted into the right to receive $25.00 per share, less any required withholding taxes, in cash and without interest, which is the same amount per share that was paid in the tender offer. The merger is expected to occur as soon as practicable. Following the merger, Omrix is expected to operate as a stand-alone entity reporting through ETHICON, Inc., a Johnson & Johnson company and Omrix's common stock will no longer list on NASDAQ.

About Johnson & Johnson

Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science -- bringing innovative ideas, products and services to advance the health and well-being of people. Our 119,400 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

Additional Information

This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of Omrix.


'/>"/>
SOURCE Johnson & Johnson
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Johnson & Johnson to Participate in Bear Stearns 20th Annual Healthcare Conference
2. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
3. Johnson & Johnson Campaign for Nursings Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program
4. Trust for Americas Health Receives $7.6 Million Grant from the Robert Wood Johnson Foundation to Advance the Quality and Impact of the Public Health System
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Johnson & Johnson Tops Annual Pharmaceutical Company Rankings in a New Report From Industry-Leading Publication Scrip
7. Independence Technology, A Johnson & Johnson Company, Renews Its Contract With Creative Technology Services
8. Johnson & Johnson Launches Global Diabetes Institute to Provide State-of-The- Art Education, Training to Health Professionals
9. Robert Wood Johnson Foundation Announces $15.6 Million Grant to Apply Power of the Archimedes Model to Critical Health Care Decisions
10. UAN Mourns Passing of President Cheryl L. Johnson, RN
11. Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... Thomas Jefferson ... Witness , was awarded a $300,000 grant from The Pew Center for Arts ... with ambiguity and the recognition of one’s own limits among health professions students. ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... $5,000 grant from the C. R. Bard Foundation, Inc. to support ... Hills , a service available through the nonprofit home care agency. Using evidence-based ...
(Date:7/21/2017)... ... 21, 2017 , ... In the first prospective ACL reconstruction ... Outcome Network (MOON) demonstrated that patients could perform sports-related functions and maintain a ... over time. The study, presented today at the American Orthopaedic Society for ...
(Date:7/20/2017)... MA (PRWEB) , ... July 20, 2017 , ... ... form of blood and bone marrow cancer that progresses rapidly without treatment. Newly ... recommended to reduce the chance of reoccurrence and relapse. With such a ...
(Date:7/20/2017)... ATLANTA, Ga. (PRWEB) , ... July 20, 2017 , ... ... and equal access to medicine for everyone affected by diabetes, is teaming up with ... the five-day global event kicks off on July 24th. , “Team Type 1’s ...
Breaking Medicine News(10 mins):
(Date:7/19/2017)...  Mako Medical Laboratories partnered with Secretary Strickland, the ... Fund (MFA) to bring 140 soldiers back home to ... families one last time before being deployed. Mako Medical ... logistics needed for these soldiers. "Mako Medical Laboratories is ... We just wish we could bring them all home," ...
(Date:7/13/2017)...  Centurion Medical Products, a leader in medical product innovation and ... removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part of a ... pain while preventing unneeded emergency department admission due to severe fecal ...
(Date:7/11/2017)... , July 11, 2017 Zymo Research Corp., also known ... that can quantify biological aging in a precise manner using the myDNAge ... Steve Horvath , a professor of human genetics and biostatistics at the ... School of Public Health , Zymo Research,s proprietary DNAge ™ technology ... ...
Breaking Medicine Technology: